5 not yet recruiting, 3 recruiting, 2 completed, 1 enrolling by invitation. 5 Phase 2, 3 Not applicable, 2 Phase 1, 1 Phase 4.
Follow Acute Lymphobkastic Leukemia: new trials by email Literature Review of Acute Lymphobkastic Leukemia trials Research Report on Acute Lymphobkastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The AYA Oncology Self-care Movement Educational Website, #AYAOSM - Acute Lymphobkastic Leukemia, Medication Adherence | Not applicable | Not yet recruiting | Northwestern University | 200 | 2026-11-01 | 2026-07-24 |
| Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia Inotuzumab Ozogamicin (IO) - Acute Lymphobkastic Leukemia, Adult | Phase 2 | Not yet recruiting | PETHEMA Foundation | 30 | 2026-10-30 | 2026-10-07 |
| This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma. CD19/22 CAR-T cells - Acute Lymphobkastic Leukemia, B Cell Lymphoma | Phase 1 / Phase 2 | Enrolling by invitation | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 17 | 2026-10-10 | 2026-10-16 |
| A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies SHB-02-CD19 (anti CD19 CAR-T cells) - B Cell Malignancies, Acute Lymphobkastic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Sheba Medical Center | 50 | 2026-06-01 | 2026-03-31 |
| Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world Acute Lymphobkastic Leukemia, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 103 | 2026-04-02 | 2026-01-21 | |
| To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004 STR-P004 - Acute Lymphobkastic Leukemia | Not applicable | Not yet recruiting | Starna Therapeutics | 11 | 2025-12-03 | 2025-11-24 |
| Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia Patients meeting criteria will receive DA-EPOCH via central line for 5 days every 21 days, with monitoring, supportive care, transfusions, prophylaxis, and G-CSF for 5 doses per cycle - Acute Lymphobkastic Leukemia, Leukemia | Recruiting | Hospital General de Mexico | 45 | 2025-07-23 | 2025-12-02 | |
| Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL Sandwich stratergy - Acute Lymphobkastic Leukemia | Phase 2 | Suspended | The First Affiliated Hospital of Soochow University | 40 | 2025-06-01 | 2026-05-29 |
| Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients Venetoclax low dose with itraconazole - Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent | Phase 2 | Recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 12 | 2025-01-02 | 2025-10-02 |
| Optimizing Recovery in Pediatric ALL Survivors: A Training Comparison Constant-load Aerobic Exercise, Graded Aerobic exercise, Structured Exercise regemin - Acute Lymphobkastic Leukemia | Not applicable | Completed | Cairo University | 72 | 2023-12-03 | 2026-06-26 |
| A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase Non-Interventional Study - Hematopoietic and Lymphatic System Neoplasm, Acute Lymphobkastic Leukemia | Recruiting | Mayo Clinic | 10 | 2023-11-02 | 2026-02-06 | |
| Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Vincristine, Daunorubicin, Prednisone - Acute Lymphobkastic Leukemia | Phase 4 | Completed | PETHEMA Foundation | 107 | 2008-01-01 | 2020-03-05 |
Leukemia (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Lymphoma, B-Cell (1) · Medication Adherence (1) · Neoplasms (1) · Recurrence (1)
Hemic and Lymphatic Diseases (4) · Neoplasms by Histologic Type (4) · Hematologic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Leukemia, Lymphoid (2) · Behavior (1) · Disease Attributes (1) · Health Behavior (1) · Leukemia (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1)
Asparaginase (1) · Blood Transfusion (1) · Cytarabine (1) · Daunorubicin (1) · Etoposide (1) · Granulocyte Colony-Stimulating Factor (1) · Inotuzumab Ozogamicin (1) · Itraconazole (1) · Mercaptopurine (1) · Palliative Care (1) · Prednisone (1) · Vincristine (1) · venetoclax (1)
PETHEMA Foundation (2) · Cairo University (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Hospital General de Mexico (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Mayo Clinic (1) · Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology (1) · Northwestern University (1) · Sheba Medical Center (1) · Starna Therapeutics (1) · The First Affiliated Hospital of Soochow University (1)
Mexico (2) · Spain (2) · United States (2) · Belarus (1) · China (1) · Israel (1) · Saudi Arabia (1)
Catherine E. Martin, PharmD, RPh (1) · Christian O Ramos, MD (1) · Ragab K Elnaggar, PhD (1)
R37CA299904 (1)